Abivax is a leading biotechnology company that specializes in developing innovative treatments to address chronic inflammatory diseases, viral infections, and cancer. As a phase 3 clinical-stage company, Abivax utilizes its immune enhancing and antiviral platforms to optimize and develop drug candidates for various conditions. With a strong focus on patients with ulcerative colitis, Crohn's disease, rheumatoid arthritis, and liver cancer, Abivax aims to provide effective and groundbreaking solutions to individuals with significant unmet medical needs.

The company leverages its immune-boosting and antiviral technologies to develop drugs like Obefazimod and ABX196 that modulate the body's natural immune system machinery. Abivax's most advanced compound, Obefazimod, has shown great promise in clinical trials, demonstrating a potent anti-inflammatory effect and potential efficacy for treating ulcerative colitis. Additionally, the company is actively preparing for clinical trials targeting rheumatoid arthritis and Crohn's disease.

Through its dedication to innovative drug development, Abivax strives to improve the lives of patients and make a lasting impact on the field of medicine